On September 5, 2025, the Ministry of Health opened a public consultation on a Draft Ministerial Order to update the Common Package of Benefits of the National Health System. The key planned changes are expected in diagnostic imaging, endocrine, gastrointestinal, in-vitro diagnostics, neurology and neurosurgery, and obstetrics and gynecology fields. Input can be submitted via email until September 26, 2025.

MTRC has released a White Paper titled "Evidence Requirements for Non-IVD Diagnostic Technologies under NICE’s HealthTech Programme". This white paper reviews five assessments of non-IVD diagnostic technologies conducted under the former Diagnostics Assessment Programme (DAP) framework. Despite procedural changes, the case studies offer enduring insights into NICE’s evidence expectations and key factors influencing recommendation outcomes. These findings can help inform evidence generation strategies and support market access planning for similar technologies under the current HealthTech framework.

On September 1, 2025, the Institute for Hospital Remuneration Systems (INeK) announced the start of the application process according to §6 (2) KHEntgG (New Examination and Treatment Methods, NUB) for 2026.

In August 2025, the Dutch Healthcare Institute (ZIN) published the report called “Assessment Framework for Feasibility of Care”. It explains how ZIN determines and assesses the feasibility of interventions when deciding on coverage within the basic health insurance.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Seppänen et al. conducted a scoping review to map interventions that reduce the environmental footprint of healthcare across multiple settings.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Champion et al. mapped the newly developed PICOTS-ComTeC framework for defining digital health interventions against 16 international and national frameworks.

On September 6, 2025, the specifications of the call for projects "Third places for MedTech experimentation" were approved. This initiative is part of the France 2030 investment plan and aims to fund the creation of collaborative testing hubs within healthcare facilities to accelerate the development and market access of innovative medical devices, with a specific focus on surgical robotics and implantable medical devices.

On September 1, 2025, the application window opened to join the 2026 NHS Innovation Accelerator (NIA) program. NIA supports the development of innovators (Fellows) and the spread of their innovation nationally. The 2026 call is not limited to a specific theme and is open to innovations addressing any health and care challenges. The application deadline is October 12, 2025.

MTRC is pleased to present the 2025 EU Prioritization Matrix for Hospital Medical Devices - your annual, refresh-and-reuse guide to strategic market entry across Europe.

On September 6, 2025, the Ministry of Labor, Health, Solidarity and Families authorized a two-year experiment on the reprocessing of certain single-use medical devices used in the cardiology field, including cardiac electrophysiology and mapping, cardiac ablation, angiography devices, and ultrasound catheters. The experiment aims to assess the technical feasibility, safety, economic impact, and environmental benefits of this practice, with a view to its permanent establishment and expansion. The experiment will start on January 1, 2026.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, van Nieuwenhuizen et al. systematically reviewed the environmental impact of operating rooms, focusing on surgical techniques, device use, cover materials, anesthesia, and ventilation.

In September 2025, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated the list of reimbursable companion diagnostics. A new clinical indication, urothelial carcinoma, was introduced, with two new predictive biomarker tests included in the List.